Nurix lands $2.3B Roche deal for bexobrutideg, receives $700M upfront

Filed July 9, 2026 · Period ending July 9, 2026 · ~1 min read

Key Changes

• high

  Nurix entered a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, receiving $700M upfront (within 30 days of closing) with potential total payments up to $2.3B including milestones.

  Exhibit 99.1 verify on EDGAR →
• high

  Companies will share U.S. development costs 40/60 (Nurix/Roche) and U.S. profits equally; Nurix receives tiered royalties on ex-U.S. sales across hematology, immunology, and neurology indications.

  Exhibit 99.1 verify on EDGAR →
• high

  Pro-forma cash position reaches approximately $1.14B including the expected $700M upfront payment, up from $443.5M as of May 31, 2026.

  Exhibit 99.1 verify on EDGAR →